Literature DB >> 18289023

Under the microscope: focus on Chlamydia pneumoniae infection and multiple sclerosis.

Enrico Fainardi1, Massimiliano Castellazzi, Silva Seraceni, Enrico Granieri, Carlo Contini.   

Abstract

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the Central Nervous System (CNS) of supposed autoimmune origin whose etiology still remains unknown. Epidemiological studies suggest that MS pathogenesis could be related to an infection superimposed on a predisposing genetic background. However, at present, no direct evidence for an infectious implication in MS autoimmunity exists. Recently, the potential role of Chlamydia pneumoniae as a causative agent of MS has received increasing attention. After the initial high rates reported for molecular and culture demonstration of C. pneumoniae in cerebrospinal fluid (CSF) of MS patients, the association between C. pneumoniae and MS was intensively investigated with controversial results. Seroepidemiological reports did not show any strong association between C. pneumoniae infection and the risk of MS. Isolation techniques failed to detect C. pneumoniae in CSF and brain tissue of MS patients. Polymerase chain reaction (PCR) evidence of C. pneumoniae in CSF and intrathecal synthesis of anti-C. pneumoniae IgG have been undetectable in MS patients or, if present, were not selectively associated with MS, but were shared by several inflammatory neurological conditions. Nevertheless, in a subgroup of MS patients, an association between PCR positivity for C. pneumoniae in CSF and disease activity was found. Intrathecal production of anti-C. pneumoniae high-affinity IgG predominated in MS progressive forms and metabolically active C. pneumoniae was identified in CSF. C. pneumoniae was recognized in CSF and brain tissue at immunohistochemical, molecular and ultrastructural levels. C. pneumoniae was also able to induce the animal model of MS. This growing body of data does not support a central role for C. pneumoniae as a candidate in MS pathogenesis, but suggests that, in a subset of MS patients, C. pneumoniae could induce a chronic persistent brain infection acting as a cofactor in the development of the disease. Thus, the actual involvement of C. pneumoniae in MS still remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18289023     DOI: 10.2174/156720208783565609

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  13 in total

1.  Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders.

Authors:  Carlo Contini; Silva Seraceni; Rosario Cultrera; Massimiliano Castellazzi; Enrico Granieri; Enrico Fainardi
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-21

2.  Anti-chlamydial IgG Neutralizing Ability in Nonzoonotic Atypical Community Acquired Respiratory Tract Infections.

Authors:  Salvatore Pignanelli; Giovanna Pulcrano; Vita Dora Iula; Alisa Shurdhi
Journal:  Indian J Microbiol       Date:  2015-05-05       Impact factor: 2.461

3.  Chlamydia pneumoniae infection, complement factor H variants and age-related macular degeneration.

Authors:  D Shen; J Tuo; M Patel; A A Herzlich; X Ding; E Y Chew; C-C Chan
Journal:  Br J Ophthalmol       Date:  2008-11-07       Impact factor: 4.638

4.  Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Carmine Tamborino; Silva Seraceni; Maria Rosaria Tola; Enrico Granieri; Carlo Contini
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

5.  Posterior reversible encephalopathy syndrome in an 87-year-old woman with Escherichia coli bloodstream infection.

Authors:  Fabio Fabbian; Marco Pala; Elisa Fallica; Jay Capone; Vincenza Cinzia Monetti; Daniela Fratti; Enrico Fainardi
Journal:  Clin Exp Nephrol       Date:  2009-10-31       Impact factor: 2.801

6.  Is C. Pneumoniae research in peril?

Authors:  Katerina Wolf
Journal:  Front Microbiol       Date:  2011-03-21       Impact factor: 5.640

7.  Chlamydia infection status, genotype, and age-related macular degeneration.

Authors:  Sam Khandhadia; Sebastian Foster; Angela Cree; Helen Griffiths; Clive Osmond; Srinivas Goverdhan; Andrew Lotery
Journal:  Mol Vis       Date:  2012-01-10       Impact factor: 2.367

8.  Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.

Authors:  Massimiliano Castellazzi; Serena Delbue; Francesca Elia; Matteo Gastaldi; Diego Franciotta; Roberta Rizzo; Tiziana Bellini; Roberto Bergamaschi; Enrico Granieri; Enrico Fainardi
Journal:  Dis Markers       Date:  2015-05-26       Impact factor: 3.434

9.  A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication.

Authors:  Dustin L Johnson; Chris B Stone; David C Bulir; Brian K Coombes; James B Mahony
Journal:  BMC Microbiol       Date:  2009-10-14       Impact factor: 3.605

10.  Qualitative and quantitative detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid from multiple sclerosis patients and controls.

Authors:  Yi-Wei Tang; Subramaniam Sriram; Haijing Li; Song-yi Yao; Shufang Meng; William M Mitchell; Charles W Stratton
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.